This is the first step in development of K1-70TM as a novel drug for improving the management of patients with Graves’ disease, patients with Graves’ ophthalmopathy, patients with thyroid cancer and other patients who would benefit from control of their TSHR activity. Here, TSHR is linked to Graves ophthalmopathy.